Showing Results for
- Academic Journals (1,541)
Search Results
- 1,541
Academic Journals
- 1,541
-
From:PLoS ONE (Vol. 7, Issue 1) Peer-ReviewedAuthor(s): Wei-Chiao Chang 10 , 12 , 15 , * , Chih-Hung Lee 13 , Tomomitsu Hirota 1 , * , Li-Fang Wang 14 , Satoru Doi 2 , Akihiko Miyatake 3 , Tadao Enomoto 4 , Kaori Tomita 5 , Masafumi Sakashita 5 , Takechiyo Yamada...
-
From:PLoS ONE (Vol. 7, Issue 12) Peer-ReviewedAuthor(s): Christiane Reitz 1 , 2 , 3 , Giuseppe Tosto 1 , Richard Mayeux 1 , 2 , 3 , 4 , 5 , * , Jose A. Luchsinger 5 , the NIA-LOAD/NCRAD Family Study Group and the Alzheimer's Disease Neuroimaging Initiative...
-
From:PLoS ONE (Vol. 9, Issue 2) Peer-ReviewedAuthor(s): Chong Wang 1, Jin-Tai Yu 1,2,3,*, Hui-Fu Wang 2, Teng Jiang 2, Chen-Chen Tan 1, Xiang-Fei Meng 1, Holly D. Soares 4, Lan Tan 1,2,3,* Introduction Alzheimer's disease (AD) is the most common type of...
-
From:PLoS ONE (Vol. 9, Issue 1) Peer-ReviewedAuthor(s): Hanneke de Waal 1,*, Cornelis J. Stam 2, Marieke M. Lansbergen 3, Rico L. Wieggers 3, Patrick J. G. H. Kamphuis 3, Philip Scheltens 1, Fernando Maestú 4, Elisabeth C. W. van Straaten 2,3 Introduction...
-
From:PLoS ONE (Vol. 9, Issue 2) Peer-ReviewedAuthor(s): Stephanie Wong 1,2,3, Emma Flanagan 1, Greg Savage 2,3, John R. Hodges 1,3,4, Michael Hornberger 1,3,4,* Introduction Behavioural variant frontotemporal dementia (bvFTD) is the second leading cause of...
-
From:PLoS ONE (Vol. 8, Issue 10) Peer-ReviewedAuthor(s): Louise Bennett 1,*, Cindy Kersaitis 2, Stuart Lance Macaulay 3, Gerald Münch 2,6,7, Garry Niedermayer 2, Julie Nigro 3, Matthew Payne 4, Paul Sheean 1, Pascal Vallotton 4, Dimitrios Zabaras 5, Michael Bird 2...
-
From:PLoS ONE (Vol. 9, Issue 3) Peer-ReviewedAuthor(s): Eliza Barnwell 1, Vasudevaraju Padmaraju 1, Robert Baranello 1, Javier Pacheco-Quinto 2, Craig Crosson 3, Zsolt Ablonczy 3, Elizabeth Eckman 2, Christopher B. Eckman 2, Viswanathan Ramakrishnan 4, Nigel H....
-
From:The Egyptian Journal of Internal Medicine (Vol. 29, Issue 4) Peer-ReviewedByline: Nevine. Hasan The Byzantine forces were routed and had withdrawn from Egypt by the year 642 AD, and thus Egypt became one of the Islamic states belonging to the Islamic caliphate [1]. Among the famous...
-
From:BioMed Research InternationalPeer-ReviewedArtemisinin is an effective component of drugs against malaria. The regulation of artemisinin biosynthesis is at the forefront of artemisinin research. Previous studies showed that AaWRKY1 can regulate the expression of...
-
From:Alzheimer's Research & Therapy (Vol. 6, Issue 4) Peer-ReviewedAuthor(s): Oscar Alzate1,2,4 , Cristina Osorio1 , Robert M DeKroon1 , Ana Corcimaru1 and Harsha P Gunawardena3 Introduction More than 5.4 million people have Alzheimer's disease (AD) in the United States, and it...
-
From:Oxidative Medicine and Cellular Longevity (Vol. 2017) Peer-ReviewedAlzheimer's disease (AD) is one of the most common neurodegenerative diseases, so far, there are no effective measures to prevent and cure this deadly condition. Ginsenoside Rg1 (Rg1) was shown to improve behavioral...
-
From:Evidence - Based Complementary and Alternative Medicine (Vol. 2017) Peer-ReviewedAlzheimer's disease (AD), the most common form of dementia, is an age-related neurodegenerative disease that is characterized by memory dysfunction, neuronal cell damage, and neuroinflammation. It is believed that...
-
From:Mayo Clinic Proceedings (Vol. 95, Issue 2) Peer-ReviewedAbstract Spinal cord injury (SCI) is a devastating condition with limited pharmacological treatment options to restore function. Regenerative approaches have recently attracted interest as an adjuvant to current...
-
From:Indian Journal of Dermatology (Vol. 65, Issue 2) Peer-ReviewedByline: Jarmila. Celakovska, Bukac. Josef, Jaroslava. Vaneckova, Irena. Krcmova, Michaela. Komorousov, Petra. Cetkovská, Radka. Vankova, Jan. Krejsek Background: Seafood allergy is among one of the common food...
-
From:International Journal of Alzheimer's DiseasePeer-ReviewedHuman clinical trials seek to ameliorate the disease states and symptomatic progression of illnesses that, as of yet, are largely untreatable according to clinical standards. Ideally, clinical trials test...
-
From:Alzheimer's Research & Therapy (Vol. 12, Issue 1) Peer-ReviewedBackground The heterogeneity within Alzheimer's disease (AD) seriously challenges the development of disease-modifying treatments. We investigated volume of the basal forebrain, hippocampus, and precuneus in atrophy...
-
From:Argumentation and Advocacy (Vol. 52, Issue 2) Peer-ReviewedThis article argues that Chaim Perelman and Lucie Olbrechts-Tyteca's concept of dissociation is a useful framework for exploring the interaction between texts and images in visual arguments. More specifically, I use...
-
From:Alzheimer's Research & Therapy (Vol. 12, Issue 1) Peer-ReviewedObjectives To investigate using quantitative EEG the (1) differences between patients with mild cognitive impairment with Lewy bodies (MCI-LB) and MCI with Alzheimer's disease (MCI-AD) and (2) its utility as a...
-
From:Alzheimer's Research & Therapy (Vol. 12, Issue 1) Peer-ReviewedBackground The What Matters Most (WMM) study was initiated to evaluate symptoms, AD-related impacts, treatment-related needs, preferences, and priorities among individuals with or at risk for Alzheimer's disease (AD)...
-
From:Journal of Clinical Investigation (Vol. 130, Issue 8) Peer-ReviewedThere are more than 7000 described rare diseases, most lacking specific treatment. Autosomal-dominant hyper-IgE syndrome (AD-HIES, also known as Job's syndrome) is caused by mutations in STAT3. These patients present...